Effects of low-intensity ultrasound opening the blood-brain barrier on Alzheimer's disease—a mini review

Effects of low-intensity ultrasound opening the blood-brain barrier on Alzheimer's disease—a mini review

Due to the complex pathological mechanisms of Alzheimer's disease (AD), its treatment remains a challenge. One of the major difficulties in treating AD is the difficulty for drugs to cross the blood–brain barrier (BBB). Low-intensity ultrasound (LIUS) is a novel type of ultrasound with neuromod...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Mengmeng Zhou, Xuanhao Fu, Boyuan Ma, Ziyu Chen, Yuelin Cheng, Linyan Liu, Shunli Kan, Xinyan Zhao, Sa Feng, Zehua Jiang, Rusen Zhu
Format:	Artykuł
Język:	English
Wydane:	Frontiers Media S.A. 2023-11-01
Seria:	Frontiers in Neurology
Hasła przedmiotowe:	low-intensity ultrasound blood-brain barrier opening Alzheimer's disease β-amyloid tau
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1274642/full

Podobne zapisy

Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
od: Iram Iqbal, i wsp.
Wydane: (2024-06-01)

Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
od: Kaden L. Nystuen, i wsp.
Wydane: (2024-01-01)

Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
od: Marcos Pais, i wsp.
Wydane: (2020-01-01)

GSK3 and Alzheimer's disease: facts & fiction …
od: Fred eVanleuven
Wydane: (2011-08-01)

The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease
od: Christina E. Murray, i wsp.
Wydane: (2018-07-01)

Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications
od: Md. Sahab Uddin, i wsp.
Wydane: (2018-01-01)

β-Amyloid Plaque Reduction in the Hippocampus After Focused Ultrasound-Induced Blood–Brain Barrier Opening in Alzheimer’s Disease
od: Pierre-François D’Haese, i wsp.
Wydane: (2020-10-01)

Pathological correlates of impaired self-awareness of memory function in Alzheimer’s disease
od: Geoffroy Gagliardi, i wsp.
Wydane: (2021-06-01)

T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease
od: Junjian Zeng, i wsp.
Wydane: (2024-04-01)

Protein phosphatase 2A dysfunction in Alzheimer’s disease
od: Jean-Marie eSontag, i wsp.
Wydane: (2014-03-01)

Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease
od: Cassia R. Overk, i wsp.
Wydane: (2009-09-01)

Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
od: Yuanxin Zhao, i wsp.
Wydane: (2022-07-01)

Evaluating Circadian Dysfunction in Mouse Models of Alzheimer’s Disease: Where Do We Stand?
od: Patrick W. Sheehan, i wsp.
Wydane: (2020-07-01)

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
od: Castillo-Carranza DL, i wsp.
Wydane: (2013-12-01)

The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome
od: Yvonne S. Davidson, i wsp.
Wydane: (2018-07-01)

Focused ultrasound therapy for Alzheimer’s disease: exploring the potential for targeted amyloid disaggregation
od: Kurt Scott, i wsp.
Wydane: (2024-08-01)

Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins
od: Stephanie R. Oatman, i wsp.
Wydane: (2023-01-01)

Implication of tau propagation on neurodegeneration in Alzheimer’s disease
od: Daniel Lamontagne-Kam, i wsp.
Wydane: (2023-07-01)

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
od: Azadeh Firouzian, i wsp.
Wydane: (2018-03-01)

The Role of MicroRNAs in Aβ Deposition and Tau Phosphorylation in Alzheimer’s Disease
od: Juanjuan Zhao, i wsp.
Wydane: (2017-07-01)

Synaptic activity and Alzheimer’s disease: a critical update
od: Davide eTampellini
Wydane: (2015-11-01)

Pyroptosis as a candidate therapeutic target for Alzheimer’s disease
od: Yuehua Huang, i wsp.
Wydane: (2022-09-01)

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
od: Linda J. Van Eldik, i wsp.
Wydane: (2024-10-01)

Dityrosine cross-linking and its potential roles in Alzheimer’s disease
od: Mahmoud B. Maina, i wsp.
Wydane: (2023-03-01)

The emerging double-edged sword role of exosomes in Alzheimer’s disease
od: Tao Liang, i wsp.
Wydane: (2023-06-01)

Sex Differences in Autophagy Contribute to Female Vulnerability in Alzheimer's Disease
od: Erin E. Congdon
Wydane: (2018-06-01)

Time between milestone events in the Alzheimer's disease amyloid cascade
od: Philip S. Insel, i wsp.
Wydane: (2021-02-01)

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
od: Donovan A. McGrowder, i wsp.
Wydane: (2021-02-01)

Is later-life depression a risk factor for Alzheimer’s disease or a prodromal symptom: a study using post-mortem human brain tissue?
od: Lindsey I. Sinclair, i wsp.
Wydane: (2023-09-01)

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
od: Javier Arranz, i wsp.
Wydane: (2024-06-01)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
od: Josef Marksteiner, i wsp.
Wydane: (2022-09-01)

Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
od: Eliasz Engelhardt, i wsp.
Wydane: (2024-12-01)

Mouse Models of Alzheimer’s Disease
od: Miyabishara Yokoyama, i wsp.
Wydane: (2022-06-01)

Trait Mindfulness Is Associated With Less Amyloid, Tau, and Cognitive Decline in Individuals at Risk for Alzheimer’s Disease
od: Cherie Strikwerda-Brown, i wsp.
Wydane: (2023-01-01)

Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder
od: Marcella Catania, i wsp.
Wydane: (2019-11-01)

Curcuminoids and resveratrol as anti-Alzheimer agents
od: Oliver B. Villaflores, i wsp.
Wydane: (2012-12-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
od: Niklas Mattsson‐Carlgren, i wsp.
Wydane: (2021-05-01)

miR‐132 loss de‐represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain
od: Evgenia Salta, i wsp.
Wydane: (2016-08-01)

The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
od: Rola Ismail, i wsp.
Wydane: (2020-05-01)

Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau
od: Hong-Qi Yang, i wsp.
Wydane: (2012-10-01)